1. Home
  2. CAF vs PLX Comparison

CAF vs PLX Comparison

Compare CAF & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley China A Share Fund Inc.

CAF

Morgan Stanley China A Share Fund Inc.

SELL

Current Price

$15.65

Market Cap

224.3M

Sector

Finance

ML Signal

SELL

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

SELL

Current Price

$2.90

Market Cap

207.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CAF
PLX
Founded
2006
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.3M
207.1M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
CAF
PLX
Price
$15.65
$2.90
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $12.00
AVG Volume (30 Days)
10.3K
★ 990.1K
Earning Date
01-01-0001
11-10-2026
Dividend Yield
★ 1.02%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.31
Revenue
N/A
★ $52,744,000.00
Revenue This Year
N/A
$64.22
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$9.85
Revenue Growth
★ N/A
N/A
52 Week Low
$15.60
$1.65
52 Week High
$21.41
$3.19

Technical Indicators

Market Signals
Indicator
CAF
PLX
Relative Strength Index (RSI) 28.87 56.51
Support Level N/A $2.08
Resistance Level $17.75 $3.19
Average True Range (ATR) 0.37 0.20
MACD -0.05 0.03
Stochastic Oscillator 6.00 71.74

Price Performance

Historical Comparison
CAF
PLX

About CAF Morgan Stanley China A Share Fund Inc.

Morgan Stanley China A Share Fund Inc is the United States based non-diversified, closed-end management investment company. Its investment objective is to seek capital growth by investing a majority of its assets in A-shares of Chinese companies listed on the Shanghai and Shenzhen Stock Exchanges. Its portfolio of investments consists of investment in different sectors such as the aerospace and defense, banks, automobiles, household durables, media, pharmaceuticals, software and other sectors.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Share on Social Networks: